Metabolex Announces Positive Results From its Clinical Study of Arhalofenate ... - PR Newswire (press release)

Metabolex Announces Positive Results From its Clinical Study of Arhalofenate ... PR Newswire (press release) ... Phase 2b trials for gout; MBX-2982, which has recently completed a Phase 2a trial in patients with type 2 diabetes; and MBX-8025, which has completed a Phase 2 trial in patients with dyslipidemia. For additional information about Metabolex and its ... and more »

Savient Pharmaceuticals: Thoughts On The Chronic Refractory Gout Market - Seeking Alpha

Savient Pharmaceuticals: Thoughts On The Chronic Refractory Gout Market Seeking Alpha The NHANES data provides an insight into the size of the gout market as a whole, but no specific information on the size of the chronic refractory gout market that Krystexxa serves. To answer this question, Savient hired a research firm to try to ... and more »

Gout treatment blog publishes information on Gout treatment relief - The Australian Eye (press release)

Gout treatment blog publishes information on Gout treatment relief The Australian Eye (press release) The editor at the Gout Treatment blog today announced the publication of a new article on gouty arthritis relief. The blog routinely publishes articles and new information about gout causes and treatments because gout affects everyone ...

Savient's Krystexxa: How I Get A 9 Million Sales Estimate By 2015 - Seeking Alpha

Savient's Krystexxa: How I Get A 9 Million Sales Estimate By 2015 Seeking Alpha The average patient enrolled was in their mid-50s and had suffered from gout for 15 years. In order to enter the trial, they had to have a baseline blood level of 8.0 mg/dl of uric acid, to have had three or more gout flares over the prior 18 months, ...